Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2-Reference-Cited by-同舟云学术

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

Published:2023-03 Issue:3 Volume:26 Page:106126
ISSN:2589-0042
Container-title:iScience
language:en
Short-container-title:iScience

Author:

Barreiro Antonio,Prenafeta Antoni,Bech-Sabat Gregori,Roca Mercè,Perozo Mur Eva,March Ricard,González-González Luis,Madrenas Laia,Corominas Júlia,Fernández Alex,Moros Alexandra,Cañete Manuel,Molas Mercè,Pentinat-Pelegrin Thais,Panosa Clara,Moreno Alberto,Puigvert Molas Ester,Pol Vilarrassa Eva,Palmada Jordi,Garriga Carme,Prat Cabañas Teresa,Iglesias-Fernández Javier,Vergara-Alert Júlia,Lorca-Oró Cristina,Roca Núria,Fernández-Bastit Leira,Rodon Jordi,Pérez Mònica,Segalés Joaquim,Pradenas Edwards,Marfil Silvia,Trinité Benjamin,Ortiz Raquel,Clotet Bonaventura,Blanco Julià,Díaz Pedroza Jorge,Ampudia Carrasco Rosa,Rosales Salgado Yaiza,Loubat-Casanovas Jordina,Capdevila Larripa Sara,Prado Julia Garcia,Barretina Jordi,Sisteré-Oró Marta,Cebollada Rica Paula,Meyerhans Andreas,Ferrer Laura

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference57 articles.

1. WHO Coronavirus (COVID-19) Dashboard. 2021;WHO,2021

2. Author Correction: a global database of COVID-19 vaccinations;Mathieu;Nat. Hum. Behav.,2021

3. Shooting at a moving target-effectiveness and emerging challenges for SARS-CoV-2 vaccine development;Günl;Vaccines (Basel),2021

4. SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies;Moyo-Gwete;bioRxiv,2021

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of the scientific literature on experimental toxicity studies of COVID-19 vaccines, with special attention to publications in toxicology journals;Archives of Toxicology;2024-09-03

2. Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results;Vaccines;2024-07-25

3. Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial;2024-04-19

4. Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months;2024-04-12

5. Protein subunit vaccines: Promising frontiers against COVID-19;Journal of Controlled Release;2024-02